Safety
?
-
Januvia (sitagliptin) Tablet
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2008, April 2011, February 2012 and October 2012
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. |
October 2012
ADVERSE REACTIONS
Post-Marketing Experience
- Arthralgia, myalgia, pain in extremity and back pain
February 2012
Summary View
DOSAGE AND ADMINISTRATION
Recommended Dosing
- The tablets must not be split, crushed, or chewed before swallowing.
PATIENT COUNSELING INFORMATION
Instructions
- Patients should be informed that the tablets must be swallowed whole and never split, crushed or chewed.
How should I take Januvia
- Take Januvia tablets whole. Do not split, crush, or chew Januvia tablets before swallowing. If you cannot swallow Januvia tablets whole tell your doctor.
April 2011
5 WARNINGS AND PRECAUTIONS
5.2 Renal Impairment
- section added
6 ADVERSE REACTIONS
6.2 Postmarketing Experience
- ...worsening renal function..
MEDICATION GUIDE
- ...worsening renal function...
July 2008
| Sections Modified | Summary of Changes to Contraindications and Warnings |
WARNINGS AND PRECAUTIONS
| WARNINGS AND PRECAUTIONS Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Januvia or any other anti-diabetic drug. |
-
-
